Insider Trading Alert - KMX, LLY And BSX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, July 2, 2014, 88 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $147.42 to $14,640,500.00.

Highlighted Stocks Traded by Insiders:

CarMax (KMX) - FREE Research Report

Grafton W Robert, who is Director at CarMax, sold 5,285 shares at $51.86 on July 2, 2014. Following this transaction, the Director owned 30,211 shares meaning that the stake was reduced by 14.89% with the 5,285-share transaction.

The shares most recently traded at $53.08, up $1.22, or 2.3% since the insider transaction. Historical insider transactions for CarMax go as follows:

  • 4-Week # shares sold: 1,474
  • 12-Week # shares sold: 1,474
  • 24-Week # shares sold: 1,474

The average volume for CarMax has been 1.9 million shares per day over the past 30 days. CarMax has a market cap of $11.5 billion and is part of the services sector and specialty retail industry. Shares are up 11.87% year-to-date as of the close of trading on Wednesday.

CarMax, Inc., through its subsidiaries, operates as a retailer of used vehicles in the United States. It operates in two segments, CarMax Sales Operations and CarMax Auto Finance. The company has a P/E ratio of 22.9. Currently, there are 8 analysts who rate CarMax a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KMX - FREE

TheStreet Quant Ratings rates CarMax as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, increase in net income, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full CarMax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 235,000 shares at $62.30 on July 2, 2014. Following this transaction, the 10% Owner owned 133.6 million shares meaning that the stake was reduced by 0.18% with the 235,000-share transaction.

The shares most recently traded at $62.50, up $0.20, or 0.32% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 865,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 1.8 million
  • 24-Week # shares bought: 29,588
  • 24-Week # shares sold: 1.9 million

The average volume for Eli Lilly and has been 4.7 million shares per day over the past 30 days. Eli Lilly and has a market cap of $70.0 billion and is part of the health care sector and drugs industry. Shares are up 22.94% year-to-date as of the close of trading on Wednesday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 3.14%. The company has a P/E ratio of 17.5. Currently, there are 5 analysts who rate Eli Lilly and a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Boston Scientific (BSX) - FREE Research Report

Mario Ernest, who is Director at Boston Scientific, sold 10,000 shares at $12.95 on July 2, 2014. Following this transaction, the Director owned 297,855 shares meaning that the stake was reduced by 3.25% with the 10,000-share transaction.

The shares most recently traded at $13.04, up $0.09, or 0.71% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 263,435

The average volume for Boston Scientific has been 12.9 million shares per day over the past 30 days. Boston Scientific has a market cap of $17.2 billion and is part of the health care sector and health services industry. Shares are up 9.23% year-to-date as of the close of trading on Wednesday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. The company has a P/E ratio of 48.1. Currently, there are 11 analysts who rate Boston Scientific a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Lowe's Snags Ex-Home Depot Exec as CEO; ISPs Face Competitive Threat -- ICYMI

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Dow Slips 178 Points; S&P 500 and Nasdaq Also Decline

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Legal Weed Sales in California Are Off to a Less Than Smokin' Start

Owner of Moviepass Sees Stock Plummet

Owner of Moviepass Sees Stock Plummet

Ford, GM Gain as China Slashes Auto Import Tariffs

Ford, GM Gain as China Slashes Auto Import Tariffs